Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Insmed, Inc. stock logo
INSM
Insmed
$96.21
-0.8%
$81.42
$60.40
$106.83
$18.25B0.92.80 million shs1.19 million shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$82.72
+4.5%
$82.10
$73.11
$126.89
$5.72B0.121.02 million shs581,189 shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$22.70
+0.4%
$22.72
$7.41
$36.91
$16.86B-1.013.81 million shs1.86 million shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$16.62
-1.4%
$17.03
$12.47
$22.80
$19.06B0.610.27 million shs6.65 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Insmed, Inc. stock logo
INSM
Insmed
-1.57%-3.67%+31.69%+49.22%+38.50%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
-0.03%-3.26%-2.89%-15.22%+0.38%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-7.13%+6.25%+9.81%+35.88%+212.29%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
-1.23%+0.48%-5.18%+24.42%+2.68%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Insmed, Inc. stock logo
INSM
Insmed
4.5613 of 5 stars
3.54.00.04.33.41.70.6
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
4.4243 of 5 stars
3.51.00.04.22.22.51.9
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.4954 of 5 stars
4.41.00.00.01.91.70.0
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
4.1993 of 5 stars
4.63.00.00.02.81.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Insmed, Inc. stock logo
INSM
Insmed
3.00
Buy$108.0712.32% Upside
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
3.00
Buy$130.5057.76% Upside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.79
Moderate Buy$34.6752.72% Upside
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
3.22
Buy$24.1345.16% Upside

Current Analyst Ratings Breakdown

Latest LNTH, TEVA, INSM, and SMMT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Insmed, Inc. stock logo
INSM
Insmed
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $111.00
7/1/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$44.00
7/1/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
6/26/2025
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$24.00 ➝ $23.00
6/23/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$122.00 ➝ $109.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$100.00 ➝ $112.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$99.00 ➝ $106.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $102.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$107.00 ➝ $119.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$94.00 ➝ $109.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Insmed, Inc. stock logo
INSM
Insmed
$381.03M47.90N/AN/A$1.60 per share60.13
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.53B3.73$7.29 per share11.34$15.65 per share5.29
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/A$0.53 per shareN/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$16.54B1.15$3.28 per share5.06$4.74 per share3.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Insmed, Inc. stock logo
INSM
Insmed
-$913.77M-$5.95N/AN/AN/A-265.93%-446.98%-52.70%8/6/2025 (Estimated)
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$312.44M$3.5223.5013.11N/A16.55%36.99%20.55%7/30/2025 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$221.32M-$0.34N/AN/AN/AN/A-62.87%-51.61%8/5/2025 (Estimated)
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
-$1.64B-$1.15N/A6.320.87-7.74%45.44%6.95%7/30/2025 (Estimated)

Latest LNTH, TEVA, INSM, and SMMT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.10N/AN/AN/AN/AN/A
7/30/2025Q2 2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.65N/AN/AN/A$389.69 millionN/A
7/30/2025Q2 2025
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$0.64N/AN/AN/A$4.34 billionN/A
5/8/2025Q1 2025
Insmed, Inc. stock logo
INSM
Insmed
-$1.36-$1.42-$0.06-$1.42$91.63 million$92.82 million
5/7/2025Q1 2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.64$1.53-$0.11$1.02$377.37 million$372.76 million
5/7/2025Q1 2025
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$0.47$0.52+$0.05$0.18$3.99 billion$3.89 billion
5/1/2025Q1 2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.10-$0.09+$0.01-$0.09N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/AN/AN/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Insmed, Inc. stock logo
INSM
Insmed
11.38
5.86
5.44
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
0.49
5.74
5.46
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
10.63
10.63
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
2.59
1.03
0.74

Institutional Ownership

CompanyInstitutional Ownership
Insmed, Inc. stock logo
INSM
Insmed
N/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
99.06%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
54.05%

Insider Ownership

CompanyInsider Ownership
Insmed, Inc. stock logo
INSM
Insmed
3.00%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
2.00%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
84.90%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
0.55%
CompanyEmployeesShares OutstandingFree FloatOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,271189.71 million184.02 millionOptionable
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
70069.19 million67.80 millionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
110742.67 million112.14 millionOptionable
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
36,8301.15 billion1.14 billionOptionable

Recent News About These Companies

Leader Capital Markets Keeps Their Buy Rating on Teva (TEVA)
Teva’s CEO shares ‘Pivot to Growth’ progress

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Insmed stock logo

Insmed NASDAQ:INSM

$96.21 -0.74 (-0.76%)
As of 03:22 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Lantheus stock logo

Lantheus NASDAQ:LNTH

$82.72 +3.53 (+4.46%)
As of 03:17 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$22.70 +0.09 (+0.40%)
As of 03:22 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$16.62 -0.23 (-1.36%)
As of 03:17 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.